Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder

Acta Psychiatrica Scandinavica

Volumn 129, Issue 5, 2014, Pages 328-342

  Cipriani, A ^a,b   Barbui, C ^b   Rendell, J ^a   Geddes, J R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Affective disorders; Antipsychotics; Bipolar disorder; Psychopharmacology; Review of the literature

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; SECOND GENERATION ANTIPSYCHOTIC; UNCLASSIFIED DRUG; ZIPRASIDONE;

BIPOLAR DISORDER; CINAHL; DATA BASE; EMBASE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAINTENANCE THERAPY; MEDLINE; PRIORITY JOURNAL; PSYCINFO; REVIEW; SCIENTIFIC LITERATURE; STUDY DESIGN; SYSTEMATIC REVIEW; ADULT; CLASSIFICATION; DRUG APPROVAL; EVIDENCE BASED PRACTICE; LEGISLATION AND JURISPRUDENCE; MEDICATION THERAPY MANAGEMENT; METHODOLOGY; NEEDS ASSESSMENT; ORGANIZATION AND MANAGEMENT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG APPROVAL; EVIDENCE-BASED PRACTICE; HUMANS; MEDICATION THERAPY MANAGEMENT; NEEDS ASSESSMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84898544482     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12223     Document Type: Review

References (29)

1. Soares-Weiser K, Bravo Vergel Y, Beynon S et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 2007;11:iii-iv, ix-206.
2. National Institute for Health and Clinical Excellence (NICE). Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care (Issue date: July 2006). Available at: www.nice.org.uk/CG038. Last accessed 31st July 2013.
3. Dias VV, Balanzá-Martinez V, Soeiro-de-Souza MG et al. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr Scand 2012;126:315-331.
4. Cipriani A, Geddes JR. What is a run-in phase? Epidemiol Psichiatr Soc 2010;19:21-22.
5. Pablos-Méndez A, Barr RG, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA 1998;279:222-225.
6. Berger VW, Rezvani A, Makarewicz VA. Direct effect on validity of response run-in selection in clinical trials. Control Clin Trials 2003;24:156-166.
7. Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011;378:1306-1315.
8. European Medicines Agency. Committee for proprietary medicinal products: note for Guidance on clinical investigation of medicinal products for the treatment and prevention of bipolar disorder, April 2001. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003528.pdf.
9. Keck PE Jr, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626-637.
10. Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163:247-256.
11. Vieta E, Suppes T, Eggens I et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008;109:251-263.
12. Suppes T, Vieta E, Liu S et al. Maintenance treatment for patients with bipolar I disorder: results from a north American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009;166:476-488.
13. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010;71:130-137.
14. Marcus R, Khan A, Rollin L et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011;13:133-144.
15. Tohen M, Chengappa KN, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-345.
16. Tohen M, Greil W, Calabrese JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162:1281-1290.
17. Weisler RH, Nolen WA, Neijber A et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: a randomized controlled study). J Clin Psychiatry 2011;72:1452-1464.
18. Carlson BX, Ketter TA, Sun W et al. Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Bipolar Disord 2012;14:41-53.
19. Ivanova A, Tamura RN. A two-way enriched clinical trial design: combining advantages of placebo lead-in and randomized withdrawal. Stat Methods Med Res 2011. doi: 10.1177/0962280211431023 [Epub ahead of print].
20. Fedorov VV, Liu T. Enrichment design. In: D'Agostino RB, Sullivan LM, Massoro JM, eds. Wiley encyclopedia of clinical trials. Hoboken, NJ: John Wiley & Sons, Inc, 2007. doi: 10.1002/9780471462422.eoct342.
21. Cipriani A, Rendell J, Geddes JR. Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol 2010;24:1729-1738.
22. Calabrese JR, Rapport DJ, Shelton MD, Kimmel SE. Evolving methodologies in bipolar disorder maintenance research. Br J Psychiatry 2001;178:S157-S163.
23. Bowden CL, Swann AC, Calabrese JR et al. Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull 1997;33:693-699.
24. Geddes JR, Goodwin GM, Rendell J et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010;375:385-395.
25. Barbui C, Baschirotto C, Cipriani A. EMA must improve the quality of its clinical trial reports. BMJ 2011;342:d2291.
26. Bulloch AG, Bresee LC, Beck CA, Patten SB. Substantial changes in prescription recommendations for bipolar disorder in Canada: 2002-2010. Can J Psychiatry 2012;57:263-268.
27. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 2011;20:177-184.
28. Ehret MJ, Levin GM. Long-term use of atypical antipsychotics in bipolar disorder. Pharmacotherapy 2006;26:1134-1147.
29. Keck PE Jr, Calabrese JR, McIntyre RS et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68:1480-1491.